Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.

Almost half of patients hospitalized for acute heart failure in Europe are readmitted within a year, according to a new study ...

The COVID pandemic didn’t just kill people directly. It appears to have accelerated a long-brewing reversal in U.S. heart failure deaths, with mortality climbing faster since 2020 after years of ...

Heart attack deaths have plummeted in recent years — but other types of cardiovascular disease still pose a major threat. A new study by the American Heart Association (AHA) found that overall heart ...

Frailty after kidney transplantation is a harbinger for death and other major adverse outcomes in hospitalized patients. The hospital frailty risk score (HFRS) predicts graft failure, severe infection ...